Comparison of Pantoprazole and Ranitidine in Dyspepsia
|ClinicalTrials.gov Identifier: NCT01737840|
Recruitment Status : Completed
First Posted : November 30, 2012
Results First Posted : July 23, 2015
Last Update Posted : July 23, 2015
The H0 hypothesis of the study is there is no difference between pantoprazole and ranitidine in treating patients presented with dyspepsia to the emergency department.
The H1 hypothesis is there is difference between pantoprazole and ranitidine in treating patients presented with dyspepsia to the emergency department.
|Condition or disease||Intervention/treatment||Phase|
|Dyspepsia||Drug: Pantoprazole Drug: Ranitidine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||66 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Intravenous Pantoprazole vs Ranitidine in Dyspepsia in Emergency Department: A Randomized Controlled Trial.|
|Study Start Date :||October 2012|
|Primary Completion Date :||January 2013|
|Study Completion Date :||January 2013|
Intravenous pantoprazole 40 mg flacon
Other Name: Pantpas
Active Comparator: ranitidine
Intravenous ranitidine 50 mg
Other Name: Ulcuran
- Visual Analogue Scale Score [ Time Frame: 30th and 60th minutes ]The investigators are measuring the change of pain from the baseline to the 30th and 60th minutes by visual anologue scale (VAS). Visual Analogue Scale measurement is between 0 (no pain) and 100 (worst pain). A decrease of 13 or 16 mm in VAS score is accepted as a minimum clinically significant change in pain.
- Need for Additional Drug [ Time Frame: 60 th minute ]The investigators are measuring the need for additional drug at the end of 60 minutes.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01737840
|Antalya, Turkey, 07050|
|Study Director:||Cenker Eken, Proffesor||Akdeniz University|